NASDAQ · Biotechnology

CTI BioPharma Corp. (CTIC) Stock

$9.10 +0.06% NASDAQ: CTIC Healthcare

CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States.

Valuation

MetricValue
Price$9.10
Market Cap$1.20B
P/E Ratio-11.51
P/B Ratio-59.35
P/S Ratio22.23
EPS (TTM)$-0.79
52-Week High$9.10
52-Week Low$4.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE505.56%
ROA-72.30%
ROCE-178.15%
Gross Margin93.49%
Operating Margin-147.91%
Net Margin-168.76%
Debt/Equity-2.84
Current Ratio1.23

Annual Financials (USD)

Metric20182019202020212022
Revenue$26.0M$3.0M$0$0$54.0M
Operating Profit$-33.0M$-41.0M$-48.0M$-95.0M$-80.0M
Net Profit$-29.0M$-42.0M$-53.0M$-100.0M$-91.0M
EPS$-0.52$-0.73$-0.74$-1.11$-0.79
Op Margin-125.1%-1217.1%——-147.9%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$90.0M$46.0M$58.0M$72.0M$126.0M
Total Liabilities$37.0M$28.0M$18.0M$69.0M$144.0M
Cash$36.0M$31.0M$40.0M$65.0M$30.0M
Borrowings$14.0M$12.0M$5.0M$51.0M$50.0M

Latest News

Argentine Football Association says US did not detain its president AFP · Jul 23, 2026 Dow Jones Futures Rise; Google, Tesla Fall On Earnings, Capex, But AI Stocks Climb Investor's Business Daily · Jul 23, 2026 HD Hyundai Heavy Industries Reaches Major Milestone in ITER Nuclear Fusion Project PR Newswire · Jul 23, 2026 PBCO Financial Corporation Reports Q2 2026 Results Business Wire · Jul 23, 2026 US announces civilian nuclear deal with Saudi Arabia AFP · Jul 23, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-40.0M$-28.0M$-42.0M$-85.0M$-81.0M
Investing Cash Flow$-31.0M$28.0M$-10.0M$12.0M$-99.0M
Financing Cash Flow$63.0M$-6.0M$61.0M$98.0M$120.0M
Net Cash Flow$-7.0M$-5.0M$9.0M$25.0M$-35.0M
Free Cash Flow$-40.0M$-28.0M$-42.0M$-85.0M$-106.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.17
EV / EBITDA-15.65
FCF Yield-8.85%
Quick Ratio1.22
Interest Coverage-6.07
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CBIO $16.84 +2.50% -6.03 $625.50M 0.00%
CINCCinCor Pharma, Inc. $29.06 +0.00% -20.46 $1.27B 0.00%
EQRXEQRx, Inc. $2.34 -2.09% 5.44 $1.14B 0.00%
ETHZEthzilla Corp. $3.53 +0.00% -0.17 $56.39M 0.00%
GRCLGracell Biotechnologies Inc. $10.25 +0.05% -1.55 $197.97M 0.00%

About CTI BioPharma Corp.

CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.

CTI BioPharma Corp. is headquartered in US.

CTI BioPharma Corp. (CTIC) stock trades at $9.10 with a market capitalization of $1.20B. The stock is valued at a price-to-earnings (P/E) ratio of -11.51, price-to-book of -59.35, price-to-sales of 22.23. Over the past 52 weeks the stock has ranged between $4.01 and $9.10, and currently trades at its 52-week high.

On profitability, CTI BioPharma Corp. generates a return on equity (ROE) of 505.56% — well above the market average, a sign of a high-quality business, return on capital employed of -178.15%, an operating margin of -147.91%, a net profit margin of -168.76%.

Official website: www.ctibiopharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides